Our article What role for ▼colesevelam? (DTB 2009; 47: 53–5) incorrectly quoted the National Institute for Health and Clinical Excellence guideline on lipid modification1 in stating that for secondary prevention of cardiovascular disease, it recommended “simvastatin 40mg daily, potentially increasing to this to simvastatin 80mg daily or a drug of similar efficacy or acquisition cost.” In reality, the latter part of this quote should have read “similar efficacy and acquisition cost”. This error does not affect the article's Conclusion.